Piper Jaffray Companies set a $25.00 price objective on Kura Oncology (NASDAQ:KURA) in a research note issued to investors on Monday morning. The firm currently has a buy rating on the stock.
Other equities analysts also recently issued research reports about the company. BidaskClub downgraded Kura Oncology from a hold rating to a sell rating in a research report on Tuesday, October 9th. HC Wainwright set a $31.00 target price on Kura Oncology and gave the company a buy rating in a research report on Tuesday, August 7th. ValuEngine downgraded Kura Oncology from a strong-buy rating to a buy rating in a research report on Friday, October 19th. Cowen restated a buy rating on shares of Kura Oncology in a research report on Monday, October 22nd. Finally, Zacks Investment Research downgraded Kura Oncology from a buy rating to a hold rating in a research report on Friday, November 9th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $26.86.
NASDAQ KURA opened at $13.60 on Monday. The company has a market capitalization of $497.52 million, a PE ratio of -8.95 and a beta of 4.41. Kura Oncology has a 1-year low of $10.20 and a 1-year high of $24.02. The company has a current ratio of 14.76, a quick ratio of 14.76 and a debt-to-equity ratio of 0.02.
Kura Oncology (NASDAQ:KURA) last released its earnings results on Monday, November 5th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.01. On average, research analysts predict that Kura Oncology will post -1.72 earnings per share for the current fiscal year.
In related news, major shareholder Ecor1 Capital Fund Qualified, acquired 119,906 shares of Kura Oncology stock in a transaction that occurred on Thursday, December 6th. The shares were purchased at an average price of $13.50 per share, for a total transaction of $1,618,731.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 15.30% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Voya Investment Management LLC purchased a new stake in Kura Oncology in the second quarter valued at $187,000. BlueMountain Capital Management LLC raised its position in Kura Oncology by 2,315.9% in the third quarter. BlueMountain Capital Management LLC now owns 10,775 shares of the company’s stock valued at $189,000 after purchasing an additional 10,329 shares during the period. Trexquant Investment LP purchased a new stake in Kura Oncology in the third quarter valued at $217,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Kura Oncology in the second quarter valued at $218,000. Finally, BB&T Securities LLC purchased a new stake in Kura Oncology in the second quarter valued at $291,000. Hedge funds and other institutional investors own 79.28% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
See Also: Treasury Bonds